Showing posts sorted by date for query epcoritamab. Sort by relevance Show all posts
Showing posts sorted by date for query epcoritamab. Sort by relevance Show all posts

Thursday, October 29, 2026

Updated European Guidelines for Treating FL

The European Hematology Association just published its updated Follicular Lymphoma guidelines in the journal HemaSphere. The guidelines are pretty comprehensive. They include recommendations for diagnosis, staging, first treatment, second treatment, and treatments after relapse. But they also include information about survivorship, which is pretty nice.

The guidelines are slightly different, I think, from those in the United States. They also are based on very recent phase III clinical trial results. So they are about as up-to-date as you can find.

I'm not going to go through all of their recommendations. I think you should read them for yourself. Here's the link again. But there are a few things from the article that I find interesting and worth highlighting.

Before I go on, this is a very good time to remind you all that I am not a medical doctor. I'm not a cancer biologist. I’m just a Cancer Nerd -- a patient with a blog who likes to read a lot. What I write is not medical advice. The best person to talk to about your disease is your own oncologist. But I hope sharing some of this makes that conversation a little easier. That's always the goal here.

One thing that I really liked to see in the abstract was this: “The median overall survival at diagnosis now likely exceeds 20 years.” That's pretty remarkable. When I was diagnosed almost 19 years ago, the literature on FL put the median survival at 8 to 10 years. We've more than doubled it in that time. I'm going to write more about that soon.

But for now here are a few thoughts from EHA guidelines. First is diagnosis. The guidelines say that about 85% of FL patience have the t(14;18) gene mutation. There are other common mutations as well, but they don't recommend testing for them, because there still really isn't enough information about them to know if it's worth knowing that a patient has a KMT2D mutation, for example. I've said this before -- there's still lots of research that needs to be done on biomarkers for FL.

In their discussion about first treatments after diagnosis, the guidelines still recommend active surveillance (or watch and wait) for asymptomatic, low tumor burden disease. They also suggest straight Rituxan is acceptable, though this treatment does not increase Overall Survival when compared to watching and waiting.

I found this especially interesting: For patients who do need treatment, Iimmunochemotherapy is the recommendation. This could be Bendamustine or CHOP along with Rituxan or Obinutuzumab. I think it’s interesting because there is so much discussion these days about “moving on” from traditional chemotherapy.  They do mention R-squared as an option for a first treatment, but looking at the research, they say the clinical trials for R-squared showed it was comparable to Immunochemotherapy but not better. The guidelines say that Rituxan (or Obinutuzumab) maintenance is an option after Immunochemotherapy. Research shows that maintenance therapy extended Progression-Free Survival, but it did not increase Overall Survival. Patients who are susceptible to infection should not receive maintenance since it lowers immunity.

As for treatment at relapse, the guidelines recognize that there are many choices. Patients with asymptomatic disease can go back to watching and waiting. But for those who need treatment, the guidelines recommend R-squared. They also recommend considering R-Squared plus either Tafasitamab or Epcoritamab. Both of these combinations showed better response rates and longer PFS then just R-squared.

For patients who progress within 24 months after immunochemotherapy, the so-called POD24 group, options include CAR-T, though CAR-T after Bendamustine may be less effective because the Bendmustine messes with the T cells that are needed for CAR-T. The guidelines mention Stem Cell Transplants, which are still used, but much less frequently than in the past. There are many more options these days.

For patients who need a third line of treatment, the guidelines suggest Bispecific Antibodies, CAR-T, Zanubrutinib, and R-squared combinations. While there are several versions of Bispecifics and of CAR-T, the guidelines don’t recommend any particular version of either. They all have strengths and weaknesses that need to be considered when dealing with each individual patient.

The last section is on Survivorship. If you've been reading the blog for the last few years, you know Survivorship is becoming more and more important to me. Survivorship is what happens after treatment it's “finished.” The guidelines point out that about 90% of FL patients have a response to their first treatment. Most patients should see their oncologist  for two years after they are finished with treatment. After that, they can see the oncologist less often. Survivorship after treatment should focus on some common long-term side effects and issues, including infections, vaccinations, cardiovascular issues, secondary cancers, fatigue, and psychological well-being. I'm very glad they included that last one. I continue to believe that cancer patients’ and survivors’ mental health is greatly ignored. Other issues that FL patients have to deal with during Survivorship include employment, financial issues, and anxiety about the disease returning. All true, and I’m impressed tat they are acknowledged in the guidelines.

As I said, I really encourage you to look at the guidelines yourself. That's especially true if you live in Europe. These guidelines are a little different from what is often recommended in the United States. And it's important to remember, as the guidelines point out, that not every treatment is available or has been approved in every country in Europe. So these guidelines are just that -- guidelines. A conversation with your doctor that includes a discussion of your own goals for treatment, your overall health, your financial picture, and your emotional state is really important. Choosing a treatment should be more than just picking the treatment with the highest numbers. There's so much more to be considered.

I did find it very interesting to read these guidelines, and to think back about what was available to me 19 years ago. Guidelines like this are constantly evolving, as they should, because the treatment landscape is constantly evolving. I think it's really interesting that treatments like Bispecifics and CAR-T, which get so much attention here in the US, are not recommended until much later in the process here. I don't think that says something bad about the European Hematological Association. I think it says something more about the oncology journalism in the United States. Doctors get very excited about those treatments, with good reason. But it's good to see that in the real world, they are one (or two) of many different types of treatments.

And that's a good thing. We have lots of options. And as these guidelines show, we have lots of very smart people who look at the very big picture to help determine which treatments, and in which order, are likely to be most effective for us.

I also think it can be a bit overwhelming to look at all of these treatments available to us and wonder how we would ever choose which one to use. But thankfully we don't have to, and it's because of those smart people.

Remember, talk to your doctor. Have those conversations even before you need to.

More soon.


Saturday, September 26, 2026

Moving Toward a Chemo-Free Future

I'm going to give you a short, easy post today because I've been using my bad arm too much this week and it hurts. I'm scheduled for surgery in a couple of weeks, and I'm trying to get as much done as I can while I still have use of both arms.

So I found a nice article called "Follicular Lymphoma: Moving Toward a Chemotherapy-Free Future," which appears on SurvivorNet and features the opinions of Dr. George (Changchun) Deng of UH Seidman Cancer Center in Ohio.

This isn't about new research. It's a kind of summary of where we are right now in terms of treatment options. If you've been reading for a while, you know I like to post this kind of article every now and then. It's nice to stop and sum things up every now and then.

Dr. Deng's main idea is that we are moving away from chemotherapy as the main treatment in Follicular Lymphoma, and moving more towards treatments that use the immune system to treat the disease. Traditional chemo can affect healthy cells as well as cancer cells. Newer treatments target cancer cells more directly. Here's a very hopeful line from the article:

"The exciting question is no longer simply whether we can control follicular lymphoma, but which immune-based treatment is best for a particular patient and when it should be used."

Among the treatments that are discussed in the article are Tafasitamab, bispecifics like Epcoritamab and Mosunetuzumab, and CAR-T. 

At the same time, chemotherapy is still around, and still an option. Just a few months ago, research suggested that R-CHOP could cure FL for many people. And chemo options are still preferred by many oncologists for transformed FL.

It's a very hopeful article, and very easy to read (SurvivorNet is aimed at patients). 

I'll rest my arm and try to right more about some newer research in a few days.  Maybe I'll do videos instead (I've got a face that was made for Tik Tok, I think.)

More soon. Stay well.

 

 

Sunday, September 20, 2026

Good News for Bispecific Mosunetuzumab

The maker of Mosunetuzumab, the bispecific, released news this week that their phase III clinical trial for Mosunetuzumab and Lenalidomide seems to be an improvement over R-Squared. I think I have received about 20 different notifications from Google Alerts about it. That's a decent indication that this is a big deal.

As you probably know, Mosunetuzumab is the first bispecific to be approved for treating Follicular Lymphoma. Bispecifics work because they have two parts. One targets a protein on the surface of the cancer cell (CD20) and the other targets a protein on an immune cell (CD3). By attaching to both, it brings the immune cell next to the cancer cell and allows the immune cell to eliminate it. 

The phase III clinical trial is called CELESTIMO. It's a two-arm randomized study, meaning the 400 or so patients in the trial are randomly given one of two treatments. So ne group received Mosunetuzumab + Lenalidomide, and the other received R-Squared (Rituxan + Lenalidomide, also known as Revlimid, which gives you the two Rs).

[I want to make a prediction here. Mosunetuzumab is also known as Lunsumio. This combination is going to end up being known as L-squared -- Lunsumio + Lenalidomide. If you're comparing it to R-Squared, this just seems inevitable. I'm all for it. I just wish this blogging program did a better job with superscripts so I wouldn't have to type out :Squared" all the time.]

The results of the CELESTIMO trial are very positive. The manufacturer says the Mosunetuzumab combination resulted in a higher PFS (Progression Free Survival) than the R-Squared, meaning it took longer for patients' disease to become get worse. The manufacturer also said there were no new side effects from combination, only those that were already known about from Mosunetuzumab and Lenalidomide separately.

The manufacturer didn't release any data to back all of this up. They said they will do that either at an upcoming medical conference or in a publication.

[Prediction #2: They'll release the results at ASH and it's going to be one of the major sessions, big enough to be held in the ballroom of the hotel. And then it will be published in the journal Blood just a few days later.]

It's a big deal, given R-Squared's history. The combination was approved in the U.S. in 2019, and it was seen as a major step forward. It was the first non-chemotherapy treatment that was shown to be as effective as traditional chemotherapy like R-CHOP or Bendamustine. Chemotherapy still has a place in FL treatment, but newer treatments are more targeted, doing less damage to healthy cells. (To be clear -- one big takeaway when R-Squared was approved was that it had different side effects than chemotherapy. Not better or worse, but different.)

So if a second non-chemotherapy treatment exists that better than both chemo and R-Squared, then that's a very big deal. We won't really know just how big a deal until the manufacturer releases the data that shows us how effective and how safe it really is.

It's also a big deal given all of the excitement that we saw over the summer from the EHA conference over a presentation on Epcoritamab and R-Squared. Epcoritamab is the second bispecific to be approved for FL, and it has been used in combination with several other treatments in different trials. I suspect the manufacturer of Mosunetuzumab released this news without any data because they wanted to remind people that Mosunetuzumab is still around and there is plenty to be excited about for their bispecific as well.

I'll keep an eye on this one. I'm pretty confident we'll get the data at ASH in a few months (though I'm also notoriously not good at predicting things.) 

More soon. I have to get a few more posts in while I can still use both arms. 


Sunday, August 23, 2026

R-Squared: A Systematic Review

The Blood Cancer Journal just published an article called "Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A Systematic Review and Meta-Analysis." 

We're at a point now where R-squared (Lenalidomide/Revlimid + Rituxan) is pretty firmly a part of our lives as Follicular Lymphoma patients. It's a standard treatment, the first option approved that showed to be as effective as traditional chemotherapy (but with a different set of side effects). It has been with us for about 7 years now as an approved treatment.

So this article is a "systemic review" of what we know about R-squared. It looks at all of the research that has been done since 2015, when the first stage 2 clinical trial results were published, on R-squared in Relapsed/Refractory FL. The aim here is to see if all of the results show the same thing, especially when compared to the AUGMENT trial that led to the approval. 

The authors wanted to look at as wide a pool as possible, so in addition to looking at just R-squared, they also looked at Lenalidomide + Obinutuzumab, which like Rituxan is an anti-CD20 monoclonal antibody. They also looked at triplets -- R-squared + some other lymphoma treatment. Finally, they looked at not just published research, but also at research that was presented at ASH, the largest hematology conference in the U.S., and EHA, the largest conference in Europe. 

Looking at so many sources of data is great, in that it gives them much more to work with. But it also complicates things. Each study had its own criteria for inclusion, so the patients across the studies don't match up with each other exactly. Some studies, especially those from the conferences, did not include all of the data that the published studies did. And some studies used slightly different dosing, so patients didn't get the same amount of the treatment across all of the studies.

All that said, they were able to do some analysis that made it possible to compare the different studies.

The results of their analysis aren't surprising -- R-squared works.

The Overall Response Rate for all of the R-squared or Lenalidomide + Obinutuzumab studies was 75.9%, and the Complete Response Rate was 39.6%. For studies involving a triplet (R-squared + another lymphoma treatment), the ORR was 85.1% and the CRR was 53.9%. This makes sense -- a third treatment will, in theory, add another way for the cancer cells to be treated. But something else happened, too, that also makes sense -- the rates of serious side effects went up, too.

In case you are curious about what the third treatment was in those triplets, they were Idelalisib; Polatuzumab; Atezolizumab; Bendamustine; ViPOR [a combination of 5 treatments, not three -- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid]; Tazemetostat; Acalabrutinib; Epcoritamab; Azacitidine; and Tafasitamab. Some of those names are probably familiar to you, and I have written about a bunch of these trials over the years. You can search for them at the top of the page.

The analysis also broke down the data in a few other ways, including prior lines of therapy. They wanted to see if R-squared was more or less effective if someone had already tried a number of other treatments. If a treatment works when others don't, that's an important piece of data.  In studies where patients had received a median of just one prior treatment, the ORR was 76.7% and the CRR was 41.9%. For patients who had received a median of two or more prior treatments, the ORR was 73.5% and the CRR was 40.5%. There was no significant difference between the two -- R-squared works well no matter how many prior treatments a patient had received. The same was true for the triplets.

As for safety, as mentioned above, there were greater numbers of serious side effects for the triplets. Serious low white blood cell counts occurred in 46.6% of triplet patients, and just 29.1% of R-squared patients. There was a trend toward serious respiratory infections in the triplet patients vs. the R=Squared patients. Low platelet counts were similar in the two groups. Patients who had to leave the study because of serious side effects were also similar -- 23.3% in the triplet group and 16.6% on the R-squared group. 

There are other data breakdowns that you can read about in the article. Click the link. 

Overall, the analysis shows the effectiveness of R-squared and begins to look at some of the effectiveness of triplets, though they are generally more recent and will need more time to see long-term results. If you've been reading for a while, you now I like those "Here's where we are" articles and videos where an expert gives us an update on things that have happened in the past. I see this as one of those articles. It's clear the R-squared is effective and safe for Refractory and Relapsed patients and provides and important option for those of us in that situation. 


Wednesday, August 12, 2026

Epcoritamab + B-R

The journal HemaSphere published new research last week on another Epcoritamab combo. It's an early trial, but it could be an effective treatment for some patients.

Epcoritamab has been getting a lot of attention lately. If you've been a regular reader, you know I've been saying for a few years that that the treatments that seem to get oncologists most excited these days are CAR-T and Bispecifics. And he bispecific that gets them most excited is Epcoritamab.

A quick reminder: a bispecific works by targeting two different proteins. One of them is on the surface of the cancer cell. So it works a lot like Rituximab, which also targets a protein on the cancer cell. But a bispecific also targets a different protein on a different cell -- a T cell, which is an immune cell. So bringing a cancer cell close to an immune cell, the bispecific helps the immune system work against the cancer. 

Epcoritamab works by targeting the CD20 protein on the cancer cell (just like Rituxan does) but also the CD3 protein on the T cell. It works very well, and there are more and more reports of it being used successfully in various combinations (like the recent presentation on Epcoritamab + R-Squared).   

In this research, the combination is Epcoritamab + Bendamustine + Rituxan. As many of you now, Bendamustine is a traditional chemotherapy. The article from HemaSphere is called "First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma." 

It's a pretty straightforward title. The article describes a phase 1b/2 clinical trial (meaning it looks at safety, like a phase 1 trial, but also effectiveness, like a phase 2 trial). The study involves 25 patients from the trial who have been diagnosed with Follicular Lymphoma but had not yet received any treatment. The patients received Epcoritamab + BR and thenwere given additional Epcoritamab for up to 2 years. 

At a median follow-up of 41.3 months, the Overall Response Rate and the Complete Response Rate were both 96%. In other words, 24 of 25 patients had a Complete Response. That's very high, and I can't remember any trial where the OR was the same as the CR. And at a median of 36 months, 87% of patients had kept that Complete Response. The 3 year Progression Free Survival was 83%, and the 3 year Overall Survival was 96%.

As for safety, the combination did not produce any new side effects, just the ones that were expected with either Epcoritamab or BR. However, those expected side effects were not minor. There was no high-grade Cytokine Release Syndrome (CRS) or ICANS (Immune Effector Cell Neurotoxicity Syndrome), which are perhaps the most serious possible side effects, though lower-grade CRS occurred in 68%. But there were other side effects. 92% of participants reported infections (a sign of a weakened immune system),   with COVID-19 being the most common (patients were enrolled in 2021). Injection site reactions in 56%. Fatigue in 52%. The most common grade 3side (more serious) side effects were infection (44%), and low white blood cell counts. In all, 72% of patients experienced a grade 3 or higher side effect of some kind.

The researchers point to the high CR rates and long duration as very positive things. But they also point out that a combination like this can potentially bring about serious side effects, and caution doctors to think very carefully about which patients would benefit from it instead of a different treatment with less serious side effects.

It's a small study, very early in the process, but probably justifies moving on to a larger study. It will be very interesting to see if the side effects become an issue. Epcoritamab is part of our future, no question. But how it ends up in our future -- as a single agent or in some combination -- will be worked out over the next few years.

 

Sunday, July 26, 2026

EHA: Surovatamig + Rituxan

 I'm still sifting through some of the abstracts from ASCO and EHA from last week, and I found another one from EHA (the European Hematology Association's annual meeting): "SUROVATAMIG (AZD0486) PLUS RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL): INITIAL SAFETY DATA FROM THE PHASE 3 SOUNDTRACK-F1 TRIAL."

(The EHA puts its titles in ALL CAPS.)

I don't know much about Surovatamig, which was previously known as AZD0486. I written about it only once before in the blog -- a description of a phase 1 trial that was reported on at the 2024 ASH conference.  Surovatamig is a bispecific, like Epcoritamab and Mosunetuzumab. It works by attaching itself to a cancerous B cell by grabbing on to the CD19 protein on the surface, and then also grabbing on to a T cell by the CD3 protein. In this way, it brings together the cancer cell and the immune cell that can eliminate it. 

The EHA presentation reports on results of a phase 3 trial called Soundtrack-F1. Let me say first of all that "Soundtrack" is a very cool name for a clinical trial. Maybe that's just because I love music so much.

Anyway, the study is looking at Surovatamig combined with Rituxan. It is a phase 3 study, with the goal of recruiting over 1000 Follicular Lymphoma patients who have not yet received teatment, though this presentation looks only at 43 of them. According to the U.S. government's clinical trials website, it has not begun recruiting trial participants in the U.S., which might be why I haven't heard much about it. Once this smaller trial is finished, the larger phase 3 trial will begin.

Still, even with only 43 patients, the researchers had some good things to present at EHA. The focus here is on safety rather than effectiveness -- reporting on the side effects experienced by the participants. The combination is interesting --  Surovatamig targets CD19, while Rituxan targets CD20. So there seems to be, at least in theory, that the two treatments would compliment each other well when used together. But any combination of treatments also means there is the possibility of doubling up the side effects.

For this study, the researchers looked at two different dose levels of Surovatamig, and divided the patients into two groups. It's very early in the trial, so median follow-up was about 6.3 months. The first group, which had a lower dose of Surovatamig, had a 95% response rate. The second group, with the higher dose, had a 100% response rate. At the time that they cut off the data to analyze it, 75% of patients in the lower dose group and 100% of patients in the higher dose group had no Minimal Residual Disease.

As for safety, 100% of patients had Treatment-Emergent Adverse Events (TEAEs), meaning side effects that develop after the treatment has been given. The most common were infusion-related reactions (36% in group 1 and 52% in group 2), mostly due to the Rituxan (not surprising to any of us who have had Rituxan). Other common side effects were fatigue (36% and 43%), muscle aches (36% and 38%) and low white blood cell counts (36% and 38%).

More serious side effects occurred in 18% of the lower dose group and 29% of the higher dose group. Cytokine release syndrome (CRS) occurred in 36% and 38% of patients and one instance of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurred in each of the groups. 

The study was specifically designed as a "safety run-in," a smaller study to test for side effects before the larger study happens. It's interesting to me that this is happening in a phase 3 study; that kind of dose escalation (testing different doses to find the best combination of safety and effectiveness) usually happens much earlier. In this case, there wasn't much difference between the two doses in terms of safety, but there was a slightly better effectiveness with the higher dose, so that will be the recommended dose for the larger phase 3 trial.

The larger phase 3 trial will be a randomized two arm study. Half of the patients will receive the Surovatamig + Rituxan combination, and the other half will receive Immunochemotherapy (R-CVP + Rituxan maintenance, R-CHOP + Rituxan maintenance, or Bendamustine + R + Rituxan maintenance). 

There are a couple of takeaways for me. The first is that Bispecifics are clearly going to be in our future as FL patients. This kind of large study isn't messing around -- they're looking for full FDA approval. Lots of newer treatments try to get accelerated approval, and they do that with smaller phase 2 trials and aiming at Refractory/Relapsed disease. This trial has neither. That tells me that Bispecifics are fully mature.    Epcoritamab and Mosunetuzumab are pretty well accepted at this point.

The other thing that strikes me is the care that is being taken to focus on safety. As far as I can tell, there has not been a phase 1 or 2 trial for this combination, but that's probably because there are already known side effects for both of the treatments involved. Still, with so much already known about other Bispecifics, it's a help the the researchers to know what to look for in this type of treatment.

As always, looking at this kind of research being presented at medical conferences tells me that we have lots to look forward to. Not every treatment in a trial will ultimately be approved. In fact, less tan 10% will likely be. But there is still lots being tested, and lots of good stuff coming.

 

Wednesday, July 15, 2026

NCCN Guidelines

It's been a while -- I don't like to go more than a week without posting. I've been busy, traveling to see some family and hosting other family members. Exhausting but fun. I wouldn't have it any other way.

But it means I'm behind on reading about Follicular Lymphoma. So I'll do my best with this one (and also mention that I'll be hosting and traveling for another week or more, so expect another delay).

As I look through all of the links that I have been collecting, the one that stands out is a video from The American Journal of Managed Care's website. It's from a series of interviews with Dr. Ryan Haumschild, Dr. Christina Poh, and Dr. Tara Graff. In the series of videos, he provides some insight into newer approvals for Follicular Lymphoma treatment. If you've been reading the blog for a while, you know I like this kind of thing, which is fairly common on oncology websites. It gives an expert a chance to tell us where we are -- a nice overview of what is happening.

The series includes nine videos, but it is video number 7 that intrigues me: "NCCN Guidelines in Focus: Key Updates for Follicular Lymphoma and Their Impact on Formulary Decisions."

The NCCN is the National Comprehensive Cancer Network, a group of 34 cancer centers that work together to produce a series of guidelines for doctors to help them make treatment decisions for many different cancers. The guides are based on current research about the best order to use different treatments. I'd link to the FL guide, but you need to sign in to read them. I can occasionally get to a copy, so I've seen what they look like.

The NCCN Guide for FL are interesting because they provide so many options. There are probably cancers that have guidelines that say "If a patient is diagnosed with stage 3 of this cancer, then treat them with X." Pretty straightforward. Of course, FL isn't like that. There are a bunch of options at every stage. In some ways, that's good -- we have lots of options. In other ways, it would be really nice to have a straight path with one option because that one option works so well.

What intrigues me about NCCN guidelines is how they are used. As I have mentioned before, in my 18 years with FL, I have seen five different oncologists. Three were Lymphoma specialists, doing research on FL and other Lymphomas. The other two were generalists, treating blood cancer patients, but also patients with breast, colon, and other cancers. Those generalists are the ones that seem to rely most heavily on the guidelines, which makes sense. After I stopped seeing one of those generalists, I found a copy of the NCCN guidelines and kind of traced our conversations through the guide. For example, he really wanted me to have a PET scan, even though there was no indication that my disease was progressing. But the NCCN guidelines said that someone in my position can have one every year, so it was OK. Now "can" is not the same as "should." I didn't get the scan, but I did get some insight into how he made his decisions. I also got a new oncologist soon after that. 

So the discussion of the updates to the NCCN guidelines was especially interesting to me. It's a short video -- the main update was that Tafasitimab + R-Squared is now in the guidelines. This combination was approved just over a year ago by the FDA, though honestly, I haven't heard much about it since then. Most of the buzz since then has been about Epcoritamab, the bispecific that was recently approved by the EU in combination with R-Squared. (Dr. Haumschild expects this combination to be approved and added to the guidelines soon.)

I liked his insight into why all of this is important. As more treatments are added to the guidelines, they are likely to be used more. And as they are used, more "real word" data is collected on how effective and safe they are outside of clinical trials. And as more data is collected, we get a better sense of which treatments are appropriate for which patients. The NCCN guidelines are based on just that kind of data.

But data doesn't tell the whole story. Oncologists are human, and have their habits and their opinions, and "the best" isn't necessarily the treatment that the data would suggest.

I guess for me, the lesson for all of this is, first, be sure you are comfortable with your oncologist. Ask questions. Have discussions. In many ways, we are lucky to have a slow-growing cancer, and one of those ways is that we often have time to have those conversations before treatment is needed. The other lesson is, seek second opinions when you can. The guidelines offer lots of options, and it's nice to have a second set of eyes look through the records and make a suggestion. 

Things will slow down for me soon, I'm sure. I'll get back to reading more of this FL stuff then. 

 Take care.

 

Tuesday, June 16, 2026

EHA: Epcoritamab and R-Squared

A reader asked me a couple of weeks ago if I reviewed presentations from the EHA Congress, the annual meeting of the European Hematology Association. It's the European equivalent of the ASH meeting in the United States. It happens soon after the ASCO conference. I have written about some EHA presentations in the past, but as I told him, I sometimes have trouble accessing their abstracts. So it hasn't been something I have done on a consistent basis. EHA has some excellent research. But it's always been a matter of access.

This year, I figured out how to look at EHA abstracts. And I had some incentive -- I got many notices about a particular presentation, "CLINICALLY RELEVANT SUBGROUP ANALYSIS FROM THE RANDOMIZED PHASE 3 EPCORE FL-1 TRIAL: TREATMENT (TX) EFFECT OF EPCORITAMAB WITH LENALIDOMIDE AND RITUXIMAB (R²) IN R/R FOLLICULAR LYMPHOMA (FL)." 

The presentation is an update on the EPCORE FL -1 clinical trial. I wrote about this a few months ago. 

First, some background. Epcoritamab is a bispecific, meaning it has two mechanisms working. On one side, it attaches to a protein on the surface of the cancerous B cell, and then also attaches to a protein on a T cell, an immune cell. In this way a bispecific uses the body's immune system to treat the cancer.

The EPCORE FL-1 trial is a phase 3 trial involving 488 patients with relapsed or refractory Follicular Lymphoma. Half of the patients received R-Squared (Lenalidomide + Rituxan) and the other half received R-Squared + Epcoritamab. The earlier results from late last year, with a median follow-up of 14.8 months, showed an Overall Response rate for the Epcoritamab group of 95% (versus 79% for the R-squared group). The Complete Response Rate was 83% for Epcoritamab and 50% for R-squared. The Progression-Free Survival for the Epcoritamab group was higher, with estimated PFS of 16 months in 85.5% of that group versus 40.2% in the R-squared group. 

The updated results break down the comparison into some sub-groups to determine if the Epcoritamab combination holds up better for certain populations. What the researchers found was that Epcoritamab + R-Squared seems to work better than R-Squared alone no matter how they divided things up. 

The results were better for the Epcoritamab group regardless of the age of the patients. For patients under 70 years old, The ORR was 96% versus 78% for the R-Squared group, and the Complete Response was 84% versus 50%. In patients 70 or older, the ORR was 91% versus 81% and the CR was 79% versus 50%. 

When patients were divided into low versus intermediate/high comorbidity (with the NHL-5 scale, a measure of how other health issues like heart, lung, or kidney disease might affect survival), the Eporitamab group again did better. Those with low NHL-5 comorbidity in the Epcoritamab group had an ORR of 94% versus 76% for the R-Squared group, and a CRR of 81% versus 50%. In the NHL-5 High/intermediate group, the ORRs were 97% versus 84% and CRRs were 86% and 49%.

The same held up for patients who received one previous treatment (ORRs were 96% vs 80%, the CRRs were 87% vs 53%,) as well as two or more previous treatments (ORRs were 94% vs 78%, the CRRs were 77% vs 45%). 

All of that matters, of course, because it shows that the Epcoritamab combination will work no matter the population. One big concern for a "triplet" like this  -- a combination of three different treatments -- is that there is the potential for three times the side effects. Patients who are older, or who have other health problems, or have been weakened by multiple treatments may have more problems with a triplet. But that wasn't the case here.

One more breakdown of the data in this presentation had to do with Lenalidomide, which has the potential for dangerous side effects. As part of the study, the researchers tried different levels of Lenalidomide -- at full strength, at 70%, and at 50%. But even with less Lenalidomide, the Epcoritamab triplet did better than the R-Squared. 

So, to sum up, Epcoritamab on its own is very good. R-Squared is very good. Combined, they are all even better, without sacrificing safety. 

I still have a few more ASCO presentations that I'm sifting through. I'll try to do the same with EHA presentations as well. More to come soon.

 

Thursday, June 11, 2026

ASCO: Bispecifics in the Real World

Another ASCO review. This one is for the presentation called "Real-world outcomes of bispecific antibodies in relapsed/refractory (R/R) follicular lymphoma (FL)."

A little background first. Bispecific antibodies are one of the two general types of treatments for FL that (in my opinion) Lymphma specialists are most excited about in the last few years, with the other being CAR-T. My own oncologist brings up bispecifics as a possiblity if I need treatment again.

Bispecifics work similarly to monoclonal antibodies like Rituxan or Obinutuzumab. Those treatments are able to seek out specific cancer cells by finding a protein on the surface of the cancer cell (CD20) and then destroying the cell. Most of us who have treatment have probably been given one or the other of those monoclonal antibodies. A bispecific also finds and attaches itself to a protein on the surface of an FL cell. But it has another side to it -- one that attaches itself to a T cell, an immune cell. This brings the T cell next to the cancer cell, and the T cell is able to eliminate the cancer cell.

Mosunetuzumab and Epcoritamab are currently the two bispecifics that are approved in the U.S. (and elsewhere). In this presentation, the researchers are interested in how well they work in the real world.

That phrase "real world" means something very specific in cancer research. It refers to how a treatment works after it has gone through clinical trials and been approved. Clinical trials are very limited in many ways. They are designed to put as much focus on the treatment being tested as possible. So clinical trials participants are limited in different ways, maybe by the number or types of treatments they have already received, or by comorbidities -- pre-existing health problems. If the trial designers are concerned that a treatment might cause kidney problems, for example, they won't let anyone with kidney disease into the trial, so if participants develop kidney problems, they know it was the treatment that probably did it.

"Real world" research doesn't have those restrictions. If a clinical trial uses an "ideal patient," a real world study includes everyone, even those who aren't ideal. A great treatment isn't so great if only a limited number of patients can actually use it.

This is a retroactive study, meaning the researchers didn't ask patients to use bispecifics. Instead, they looked back at records of patients who did use them to see how safe and effective they were, especially compared to the clinical trials. A total of 99 patients with Relapsed/Refractory FL were studies. 92 of them had received Mosunetuzumab and 8 received Epcoritamab (Mosunetuzumabhas been available longer). It was a diverse group by age (raging from 33 to 101 years old) and treatment history (ranging from 1 to 14 prior treatments), including 15 who had received CAR-T.

The results were very positive. They were able to collect data from 96 patients. The Overall Response Rate to a bispecific was 87%, including a Complete Response Rate of 72%.  The responses were not significantly associated with other factors like which bispecific they received, their FLIPI score, or whether or not they had received CAR-T. All of them were successful.

The Progression Free Survival rate at 12 months was 72%, and at 18 months was 56%. Overall Survival rate were 94% and 92%. PFS was not influenced by those factors like FLIPI score or CAR-T use. 

As for safety, 34% of patients had CRS (Cytokine Release Syndrome), though none were grade 3 or higher, which is the most serious levels. Only 3% of patients had ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome). Again, side effects were not assocaited with the other factors mentioned above. 

I'm leaving out some details, which you can see yourself in the abstract. But the conclusion remains the same. This retrospective study included a diverse group of patients who had received lots of previous treatments, and the two bispecifics were effective and safe for most of them, including patients who were very elderly (did you catch that one of them was 101 years old?). They held up well in the real world.

It's important confirmation for a popular and exciting treatment.

A few more ASCO reviews to come soon.

 

Tuesday, April 21, 2026

Epcoritamab + R-Squared (+ Pharmacists)

In my quest for some Follicular Lymphoma-related reading material during this slow news time, I found an article in Pharmacy Times called "Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1." 

As you can guess, Pharmacy Times is aimed at pharmacists, the folks who manage and sometimes advise on medications. That's the angle that makes it kind of interesting.

It's mostly a summary of the EPCORE FL-1 clinical trial results. EPCORE is the general name for a series of studies that have looked at the bispecific Epcoritamab. The EPCORE NHL-1 study looked at patients with several types of Non-Hodgkin's Lymphoma who were treated with just Epcoritamab. The EPCORE  FL-1 study is the one described here, and is the one that got people very very excited at last year's ASH conference.  This trial involves only FL patients, and combines Epcoritamab with R-Squared (Rituxan + Revlimid, also known as Lenalidomide).

The article provides a good overview of all of the successful trials for Epcoritamab, and especially for EPCORE FL-1. This was a phase 3 global study, with 488 patients from 30 countries. Patients had refractory or relapsed disease and had previously received a monoclonal antibody + chemotherapy. Patients were divided into two groups: one received R-squared and the other received R-squared plus Epcoritamab. 

Results were very positive. After a median follow-up of 14.8 months, The Epcoritamab group had a 95% Overall Response Rate (versus 79% for the R-squared only group). Most other measures were better in the Epcoritamab group did better than the R-squared only group -- including Progression Free Survival, Duration of Response, and Time to Next Treatment. It's easy to see why people were so excited at ASH.

Safety was also good, with low white blood cells counts (neutropenia) and infections being the most common side effects. Cytokine Release Syndrome, a major concern, occurred in 26% of patients, but all cases were manageable. Other side effects are described in the article. This isn't really providing any new data, just a summary of what was already reported.

What I found so interesting, though, were the "pharmacy" aspects of the article.

For instance, the article goes into some detail about dose escalation, something that gets mentioned in most oncology articles, but not in much detail.

In the EPCORE FL-1 trial, the dosing was changed partway through. At first, patients received a smaller dose first, and then a larger second dose. But in later studies, it was divided into three steps instead of two, so patients received it more gradually. Researchers think this probably helped lessen the severity of some side effects, including CRS. 

It also goes into some detail about "premedications" -- intravenous hydration, an antihistamine, an antipyretic (like acetaminophen), and corticosteroids (preferable dexamethasone) -- as well as "postmedications," including two to three liters of oral fluids within 24 hours after receiving Ecoritamab, plus corticosteroids (dexamethasone again) for 3 days.

I can picture an oncology pharamacist reading the results of the EPCORE FL-1 in an abstract, and thinking "That's nice, but what were the premedications?!" 

And I say that with great admiration, from one amateur Cancer Nerd to a professional one.

I don't really think about the role that pharmacists play in our treatment. 

When I had my Rituxan infusions, I had a blood draw first. Then I met with the oncologist to make sure everything was OK and I was well enough for the day's dose. Then I went to the treatment room, where the excellent Nurse Sue took care of me for a few hours. But somebody had to prepare the Rituxan. Somebody had to worry about my premedication hydration and the antihistamine I needed when I had an allergic reaction. 

It's kind of cool to think that there's someone else behind the scenes, keeping an eye on things. The size of our care team is really large.

I don't ever remember talking to a pharmacist when I needed treatment, but education is certainly a job for pharmacists, and the article discusses the role that pharmacists can play when a patient needs education about any of the medications that are a part of this treatment process. 

It's just kind of nice to have a broader perspective on things. It's one more person who cares about us, and who is looking out for us. We're lucky to have these hidden angels.  


Wednesday, January 7, 2026

More ASH Reviews

 I'm going through all of the links I have saved from the last month or so, and I have a few more related to ASH that are worth sharing, Not necessarily any new information, but at the very least, it's confirmation that some good things were presented at the conference last month.

The website Medscape published two video reviews of the conference.  The first is called "ASH 2025: The Clinical Impact of New Therapies and Long-Term Outcomes in Follicular Lymphoma." It features Dr. Kami Maddocks of The Ohio State University. She discusses some of the more important presentations at ASH, and focuses on clinical impacts -- how the new information might directly affect current patients.

Of course, she focuses on the data related to Epcoritamab + R-Squared, which she says is "going to change practice." In other words, we're likely to see it recommended for patients who have Relapsed or Refractory disease who are need of a treatment option. She also mentions Tafasitamab plus R-Squared, and the issues related to sequencing CD19-directed therapies. That is, patients who received Tafasitamab kept the CD19 protein on their cancer cells, meaning a teatment like CAR-T, which targets CD19, should be used after Tafasitamab, not before. (The presentation that discussed this was also on The Leonard List for this year.)

Dr. Maddocks also mentions the research that looked at long-term (20 year) follow-ups of FL patients, which found that 40% of patients who received immunochemotherapy (like R-CHOP or R-Bendamustine) were still disease-free after 15 years. And about 20% of patients who watched and waited continue to do so for 15 years. Finally, this study also showed that the risk of Transformation to a more aggressive Lymphoma decreases after 10 years. Dr. Maddocks says this is all important information when oncologists counsel FL patients about long-term outcomes. (This all sounds very familiar to me, but I can't find a link for this presentation, unfortunately, and the video doesn't include it. But it's great news -- I love a good long-term follow-up.) Finally, she discussed the research about GLP-1s and indolent Lymphomas including FL, something else that was on The Leonard List. (You might remember that I was hesitant to discuss that one. Dr. Maddocks thinks it looks very interesting, but there needs to be more data collected about it.)

So lots of good information, with the focus on how it all plays out right now in the doctor's office.

The second video review from Medscape is called "New Options in Follicular Lymphoma From ASH 2025," and features Dr. Michael R. Bishop from the University of Chicago. As the title suggests, Dr. Bishop is interested in some of the new treatments that were presented at ASH. Of course, he starts with Epcoritamab (because that's what everyone is excited about -- he calls it "The Big News" from the conference. He also mentions the presentation on Epcoritamab + R-Squared in untreated FL. He wants to see long-term follow-up to make sure the excellent responses will last, and he points out that it was a very small trial.

 Dr. Bishop also looks at a presentation on the CAR-T known as Liso-cel. In this research, Liso-cel was given to FL patients who were "heavily pre-treated" -- who had already received at least two other treatments. The results were great -- a 97% Overall Response Rate, including a 94% Complete Response. After 36 months, 75% of patients had not yet needed another treatment.  (Sorry -- I don't have a link for this one, either, but it's no surprise that a CAR-T was effective, though Dr. Bishop did point out that there were some secondary cancers in some patients.)

He also discussed another of The Leonard List presentations, this one looking at the Gallium Trial, showing that mutations in EZH2 and CREBBP could help predict success with Bendamustine. This research is important in showing how biomarkers can help guide treatment.

So, again, not much that hasn't been covered already, but I do think it's important to show that multiple Lymphoma experts see certain research as moving us forward. It's hard to see that when just reading abstracts. I enjoy hearing experts tell me what excited them after the conference is over. If you've ever been to a professional conference of any kind, there's a special kind of magic that you feel afterwards, when you have all of this new knowledge that's really exciting. These videos capture just a little bit of that.

More soon. 

 

Tuesday, January 6, 2026

A Few Approvals

Hello all, and welcome to 2026.

It's been a week since I have posted. I usually try to get something up a little sooner than that. But I started the new year with some computer problems, and it's taken a few days to get things fixed. Thankfully, I'm back to writing. I supposed I could have written a blog post on my phone, but honestly, I'm just too old for that. The buttons are too small, the words are too small, and my patience is too small. I wear progressive lenses for a reason. 

On a related note, Spotify gave me my "Listening Age." If you are unfamiliar, the music steaming service Spotify ends the year by giving you some data about your listening -- the songs or artists you listened to most -- that kind of thing. But they also give you a "Listening Age," a measurement of how old the music is that you listen to. So if you listen to a lot of contemporary music, you'll have a young Listening Age. My Listening Age is 69. I'm not only too old to write with my phone, I'm also too old to listen to anything that wasn't played at my high school prom.

So, just to sum up: 

My biological age is 58.

My Listening Age is 69.

My Lymph Node Age is about 93.

Just so you know what you're dealing with as we enter the new year.

**********

Unfortunately, I also have a hard time reading on my phone, so I'm behind on Lymphoma news to share with you.

So I'll pass along some of the approval news that has happened in the last few weeks. I haven't been able to share it because I have been focused on ASH.

The big Follicular Lymphoma approval news has been the FDA approval of subcutaneous Mosunetuzumab.  Mosunetuzumab was the first bispecific approved for FL (though Epcoritamab has been in the news a lot more lately). A quick reminder -- bispecifics work by attaching themselves to cancerous B cells, and then also to T cells, which are immune cells that can eliminate the cancer cells. Up until now, Mosunetuzumab has been administered intravenously, through a vein in the arm, over a period of 2 to 4 hours. With the subcutaneous injection, that time is reduced to about 1 minute. A clinical trial showed that the subcutaneous version was as effective and as safe as the IV version. This is, if nothing else, a Quality of Life issue, with less time spent in a hospital or clinic, and more time doing other things. Ideally, this will also bring the cost down. 

In non-USA approval news, the European Union approved Minjuvi (Tafasitamab) plus R-Squared (Revlimid/Lenalidomide and Rituxin) for patients with Relapsed or Refractory Follicular Lymphoma. I wrote about this in November, when it had been given it's almost-approval, but now it's official.

Also, Japan's Japan's Ministry of Health, Labour and Welfare approved the same Tafasitamab for the same population. I briefly mentioned both of these approvals in my "predictions" post, but I thought they deserved a little bit more attention than I gave them then.

There are a few more interesting FL-related articles that I have seen fromm the last few weeks. My old eyes will have an easier time reading them, and my old fingers will have an easier time writing about them, so look for them soon. And of course, look for my diagnosiversary post next week. I'll have some things to say.

 

Tuesday, December 30, 2025

How Were My 2024 Predictions?

This will be my last post for 2025, so I want to revisit my last post from 2024, called "Year-End Predictions." Just for fun, I made three predictions about Follicular Lymphoma for 2025.

I'm guessing a lot of you saw the calendar turn to December a few weeks ago and thought, "I wonder how Lympho Bob's year-end predictions went? I've been dying to know if he was right, because he's always so right about everything!"  Well, here we go. Your wish is about to come true.

My first prediction was "Tafasitamab won't be the 'game-changer' that the headlines predict it will." I was right about this.

At last year's (2024) ASH conference, there was a lot of excitement about Tafasitamab (also known as Monjuvi). Tafasitamab is a monoconal antibody, and the results of a stage 3 clinical trial were presented at ASH, where Tafasitamab was combined with R-Squared (Rituxan and Lenalidomide).  I had written about it a few times after ASH. There were lots of commentaries that talked about how great the combination was, and how it would most likely mean Tafasitamab + R-Squared would become the default treatment for Relapsed/Refractory Follicular Lymphoma. That hasn't happened. As I wrote a year ago, it takes a lot to change an oncologist's habits, and unless there is a huge change in survival statistics, there will probably be some change, but not a lot of change. The "game-changer" headlines are often clickbait, getting people like me and the rest of you Cancer Nerds all excited and reading their articles. It seems like there is always some new great treatment that will change things for us. To be sure, treatments are getting better over time (the difference in the choices I had when I was diagnosed about 18 years ago, and those available now, is incredible.) But as I get older, I get more suspicious of news articles that are a little too excited about these things. Tafasitamab may end up being an important part of our treatment choices, but it isn't yet. It was approved by the EU a week ago, and by the Japanese health ministry about the same time.

My second prediction was "Epcoritamab will cause some concerns." Epcoritamab was another treatment that caused some excitement at the 2024 ASH conference. But it also caused some controversy. The effectiveness numbers were great, but the safety raised some questions. There were a few more deaths than were expected, but they were explained by the fact that the trial took place during the Covid pandemic, when some of the trial participants had lowered immunity. As I said in the post, "my gut tells me those concerns haven't been completely answered." Well, as you know if you've been reading lately, Epcoritamab was this year's darling at ASH, and the "game changer" language for Tafasitamab from last year was applied to Epcoritamab for this year. So I'm going to say I was wrong about this one. There were no new safety issues in the year that followed, and Epcoritamab might well be the great treatment that the headlines say it will be. I sure hope so -- the numbers are fantastic. But time will tell.

My third prediction was "There won't be any major changes to the FDA approval process." I'm thinking I'm right about this one, too. Last year, there was talk that the FDA might cut back on surrogate endpoints and focus more on Overall Survival. In other words, they would ask for more long-term data before making decisions, That didn't happen, but there was plenty of controversy at the FDA anyway. I won't get into it. If you live in the U.S. and you follow health news, then you know. There has been a change in leadership, some instability in key positions, and controversies in many areas of pubic health. I was hoping to find a link to an objective source that described the year that the FDA had, but I couldn't find one. I will say, despite the controversies, it doesn't seem to me that the oncology world was effected negatively by it. FL treatments were approved, and people remain excited. The approval process has been largely the same as it was before. We'll stay hopeful that it stays that way, and if it does change, it will be change for the good.

There are a couple of lessons here.

First, I'll say what I said last year when I made the predictions -- remember that I'm not an oncologist or a cancer biologist. When it comes to cancer advice, the best person to talk to is your own oncologist. It's fun to make predictions, but I'd never make a prediction that I thought would affect an individual's life. I wouldn't want that responsibility -- that's not fun. Sure, I got two right, but the one I got wrong, I got really wrong. If your oncologist is a Lymphoma specialist, ask them what gets them excited about Lymphoma research these days. Then watch their eyes get big and their voice get a little louder from excitement. That's the real fun.

The other lesson is a reminder that one year is not a lot of time when it comes to cancer research. We move forward, but in small steps -- rarely in giant leaps. And we don't know for a while just how big a leap it is. Best to enjoy the small victories when we get them, and hope they turn into something big.

I hope your 2025 finishes up wonderfully, and your 2026 brings you good health and happy times.

I'll be back next year. Still lots of small victories to write about.

Take care.